Read this article in:
Basel, Switzerland-based Noema Pharma, a clinical-stage biotech company, announced on Tuesday that it has raised CHF 103M (approximately €103.5M) in an oversubscribed Series B round of funding co-led by European healthcare-focused investment firms Forbion and Jeito Capital.
PMC Enterprises and an additional new investor also joined existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare, and Invus in the round.
As a part of the funding, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join Noema Pharma’s Board of Directors.
The announcement comes three years after raising CHF 54M in a Series A funding round in December 2020.